BeStock  
Stocks › Biotechnology › GPCR

Structure Therapeutics GPCR

US equityMarket cap rank #3061Biotechnology
$16.13 −$0.99 (-5.78%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $16.69 +3.47%
Open$16.73
Prev close$17.12
Day range$16.06 – $17.08
Volume786.2K
Market cap$1.15B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$156.33M-111.9% YoY
Net profit-$144.76M-120.3% YoY
Diluted EPS-$1.98-78.4% YoY
Free cash flow-$105.35M-100.4% YoY
Operating cash flow-$101.70M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-36.5MDec '24$-46.8MMar '25$-61.7MJun '25$-65.7MSep '25$33.0MDec '25$-76.0MMar '26$-106.2MJun '26$-144.8MSep '26

Diluted EPS by quarter

-0.64Dec '24-0.81Mar '25-1.08Jun '25-1.11Sep '250.47Dec '25-1.05Mar '26-1.47Jun '26-1.98Sep '26

Free cash flow by quarter

$-36.5MDec '24$-52.5MMar '25$-54.8MJun '25$-52.6MSep '25$-65.9MDec '25$14.1MMar '26$-120.1MJun '26$-105.3MSep '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-29.5%
Return on assets-27.1%
Return on invested capital-29.3%
Current ratio11.91
Liabilities / assets8.4%
Cash & investments$1.24B
Total debt$4.07M
Net cash (debt)$1.24B

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $156.33M $118.63M $89.38M $186.81M -$13.74M
Selling and Admin Expenses $21.78M $18.57M $22.87M $61.55M $17.57M
-General & Admin Expense $21.78M $18.57M $22.87M $61.55M $17.57M
Research & Development $134.55M $100.06M $66.51M $225.26M $68.69M
Operating Profit -$156.33M -$118.63M -$89.38M -$186.81M $13.74M
Net Non-Operating Interest Income (Expense) $11.75M $12.71M $13.60M $35.87M $9.19M
Total Other Finance Costs -$11.75M -$12.71M -$13.60M -$35.87M -$9.19M
Pretax Profit -$144.59M -$105.93M -$75.78M -$140.69M $33.17M
Tax $171,000.00 $234,000.00 $190,000.00 $515,000.00 $170,000.00
Net Profit -$144.76M -$106.16M -$75.97M -$141.20M $33.00M
Profit from Continuing Operations -$144.76M -$106.16M -$75.97M -$141.20M $33.00M
Net Income to Parent Company -$144.76M -$106.16M -$75.97M -$141.20M $33.00M
Net Income to Common Stockholders -$144.76M -$106.16M -$75.97M -$141.20M $33.00M
Basic EPS -$1.98 -$1.47 -$1.05 -$2.40 $0.47
Diluted EPS -$1.98 -$1.47 -$1.05 -$2.40 $0.47
Other Operating Expenses – – – -$100.00M –
Other Income (Expense) – – – $10.25M –
Special Income (Charges) – – – $10.25M –
-Gain on Sale of Property/Plant/Equipment – – – $10.25M –

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.33B $1.43B $1.51B $1.58B $1.58B
Total Current Assets $1.28B $1.37B $1.49B $1.57B $1.57B
Cash and Cash Equivalents & Short-Term Investments $1.24B $1.34B $1.46B $1.45B $1.45B
-Cash and Cash Equivalents $222.03M $272.64M $316.17M $799.62M $799.62M
-Short Term Investments $1.02B $1.07B $1.14B $646.57M $646.57M
Receivables $0.00 $0.00 $0.00 $100.00M $100.00M
Other Current Assets $35.15M $29.37M $32.09M $24.11M $24.11M
Total Non-Current Assets $59.29M $53.39M $17.53M $13.62M $13.62M
Net PPE $16.84M $12.39M $11.97M $12.90M $12.90M
-Gross PPE $16.84M $12.39M $11.97M $15.87M $15.87M
Other Non-Current Assets $42.46M $41.00M $5.56M $717,000.00 $717,000.00
Total Liabilities $112.55M $71.01M $61.03M $67.54M $67.54M
Total Current Liabilities $107.10M $66.11M $56.98M $63.29M $63.29M
Payables $33.88M $11.13M $7.82M $13.86M $13.86M
-Accounts Payable $33.88M $11.13M $7.82M $13.86M $13.86M
Current Accrued Expenses $58.33M $44.37M $40.19M $34.11M $34.11M
Short-Term Debt and Capital Lease Obligation $2.76M $2.60M $2.61M $2.88M $2.88M
-Current Capital Lease Obligation $2.76M $2.60M $2.61M $2.88M $2.88M
Total Non-Current Liabilities $5.45M $4.90M $4.05M $4.26M $4.26M
Long Term Debt and Capital Lease Obligation $4.07M $3.63M $3.18M $3.61M $3.61M
-Long Term Capital Lease Obligation $4.07M $3.63M $3.18M $3.61M $3.61M
Other Non-Current Liabilities $1.38M $1.27M $863,000.00 $647,000.00 $647,000.00
Total Equity $1.22B $1.35B $1.45B $1.52B $1.52B
Stockholders' Equity $1.22B $1.35B $1.45B $1.52B $1.52B
Capital Stock $21,000.00 $21,000.00 $21,000.00 $21,000.00 $21,000.00
-Common Stock $21,000.00 $21,000.00 $21,000.00 $21,000.00 $21,000.00
Additional Paid-In Capital $2.02B $2.01B $2.00B $1.99B $1.99B
Retained Earnings -$797.18M -$652.43M -$546.27M -$470.30M -$470.30M
Gains/Losses Not Affecting Retained Earnings -$4.69M -$3.45M -$2.20M $1.05M $1.05M
-Other Receivables – – – $100.00M $100.00M
-Accumulated Depreciation – – – -$2.97M -$2.97M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$101.70M -$120.12M $15.23M -$222.20M -$64.42M
Net cash flow from continuing operations -$101.70M -$120.12M $15.23M -$222.20M -$64.42M
Net Income from Continuing Operations -$144.76M -$106.16M -$75.97M -$141.20M $33.00M
Depreciation & Depletion & Amortization $61,000.00 $551,000.00 $576,000.00 $1.33M $412,000.00
Other Non-Cash Items $738,000.00 $764,000.00 $649,000.00 $2.56M $940,000.00
Change in Working Capital $32.70M -$24.51M $81.58M -$88.04M -$93.83M
-Change in Receivables $0.00 $0.00 $100.00M -$100.00M -$100.00M
-Change in Prepaid Assets -$5.78M $2.72M -$7.99M -$16.41M -$9.13M
-Change in Payables and Accrued Expense $40.48M $8.82M -$5.10M $26.28M $10.02M
-Change in Other Current Assets -$1.46M -$35.44M -$4.84M $4.39M $5.88M
-Change in Other Current Liabilities -$539,000.00 -$619,000.00 -$489,000.00 -$2.30M -$603,000.00
Net cash flow from investing $50.36M $74.50M -$496.95M $89.80M $56.14M
Net Cash Flow from Continuing Investing Activities $50.36M $74.50M -$496.95M $89.80M $56.14M
Net PPE Purchase and Sale -$3.65M $42,000.00 -$1.18M -$3.61M -$1.50M
Net Investment Purchase and Sale $54.01M $74.46M -$495.77M $93.41M $62.79M
Financing Cash Flow $734,000.00 $2.09M -$1.74M $762.52M $704.99M
Net Cash Flow from Continuing Financing Activities $734,000.00 $2.09M -$1.74M $762.52M $704.99M
Proceeds from Stock Option Exercised $1.23M $2.09M $869,000.00 $99.45M $97.59M
Net Other Financing Charges -$500,000.00 $0.00 -$2.61M -$2.64M -$1.25M
Ending Cash Balance $222.03M $272.64M $316.17M $799.62M $799.62M
Net Change in Cash -$50.61M -$43.53M -$483.46M $630.11M $696.71M
Beginning Cash Balance $272.64M $316.17M $799.62M $169.51M $102.91M
Free Cash Flow -$105.35M -$120.07M $14.05M -$225.81M -$65.91M
Gain/Loss from Continuing Operations – – – -$10.25M –
Net Common Stock Issuance – – – $665.71M $608.65M

Discussion

No comments yet — be the first to weigh in on GPCR.

Sign in to join the discussion.

Scroll to Top